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STUDY QUESTION: When should ‘not so rare’ Leydig cell tumors (LCTs) of the testis be suspected, diagnosed, and treated?
SUMMARYANSWER: LCTs aremore frequent than generally believed, are associatedwithmale infertility, cryptorchidism and gynecomastia,
and should be treated conservatively (in compliant patients) with active surveillance, which appears to be a safe alternative to surgical
enucleation.
WHAT IS KNOWN ALREADY: Increasing referrals for testicular imaging have led to an increase in findings of LCTs. The features and
natural history of these tumors remain largely unknown, as the available studies are small and heterogeneous. LCTs were previously treated
aggressively and follow-up data are lacking.
STUDY DESIGN, SIZE, DURATION: A case-cohort study of consecutive patients diagnosed with LCTs over a 10-year period was
prospectively enrolled from 2009 to 2018 and compared to matched cohorts of patients with seminomas or no testicular lesions screened in
the same timeframe.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Of the 9949 inpatients and outpatients referred for scrotal ultrasound, a total
of 83 men with LCTs were included. Enrolled subjects underwent medical history and clinical examination and were asked to undergo routine
blood tests, hormone investigations (FSH, LH, total testosterone, estradiol, inhibin B, sex hormone-binding globulin (SHBG), prolactin), and
semen analysis. Patients who consented also underwent contrast-enhanced ultrasound, elastography, gadolinium-enhanced scrotal magnetic
resonance imaging, and hCG stimulation test (5000 IU i.m.) with serum total testosterone and estradiol measured at 0, 24, 48, and 72 hours.
MAIN RESULTS AND THE ROLE OF CHANCE: In total, 83 patients diagnosed with LCTs were compared against 90 patients diagnosed
with seminoma and 2683 patients without testicular lesions (NoL). LCTs were diagnosed by enucleation (48.2%), orchiectomy (13.3%), or
clinical surveillance (38.5%). Testicular volume, sperm concentration, and morphology were lower (P = 0.001, P = 0.001, and P < 0.001,
respectively) in patients with LCTs than in the NoL group. FSH, LH, and SHBG were higher and the testosterone/LH ratio was lower in LCTs
than in the NoL group (P < 0.001). The LCT group showed higher SHBG (P = 0.018), lower sperm concentration (P = 0.029), and lower
motility (P = 0.049) than the seminoma group. Risk factors for LCTs were cryptorchidism (χ2 = 28.27, P < 0.001), gynecomastia (χ2 = 54.22,
P < 0.001), and low testicular volume (χ2 = 11.13, P = 0.001). Five cases were recurrences or bilateral lesions; none developed metastases
during follow-up (median, 66 months).
LIMITATIONS, REASONS FOR CAUTION: This study has some limitations. First, hCG and second-line diagnostic investigations were
not available for all tumor patients. Second, ours is a referral center for infertility, thus a selection bias may have altered the baseline features
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of the LCT population. However, given that the comparison cohorts were also from the same center and had been managed with a similar
protocol, we do not expect a significant effect.
WIDER IMPLICATIONS OF THE FINDINGS: LCTs are strongly associated with male infertility, cryptorchidism, and gynecomastia,
supporting the hypothesis that testicular dysgenesis syndrome plays a role in their development. Patients with LCTs are at a greater risk
of endocrine and spermatogenesis abnormalities even when the tumor is resected, and thus require long-term follow-up and prompt efforts
to preserve fertility after diagnosis.
LCTs have a good oncological prognosis when recognized early, as tissue-sparing enucleation is curative and should replace orchiectomy.
Conservative surgery and, in compliant patients, active surveillance through clinical and radiological follow-up are safe options, but require
monitoring of testicular failure and recurrence.
STUDY FUNDING/COMPETING INTEREST(S): The project was funded by the Ministry of University and Research Grant MIUR
2015ZTT5KB. There are no conflicts of interest.
TRIAL REGISTRATION NUMBER: ALCeP trial (ClinicalTrials.gov Identifier: NCT01206270).
Key words: Leydig cell tumors / testicular dysgenesis syndrome / organ-sparing surgery / Leydig cell failure / testicular cancer
Introduction
Leydig cell tumors (LCTs) are the most common form of testicular
stromal tumor. Although once considered rare, in the most recent
series, they accounted for 3–22% of all testicular neoplasms (Isidori
et al., 2014; Lagabrielle et al., 2018; Paffenholz et al., 2018). Most
LCTs are benign, with an exceptionally low number of metastasiz-
ing cases reported to date (Nason et al., 2017). However, the lim-
ited number of available studies prevents an understanding of the
true natural history of the disease. The management of LCTs in
terms of treatment, clinical implications, and follow-up thus remains
controversial.
As the therapeutic options for LCTs differ from those for the more
common—and more aggressive—germ cell tumors, preoperative
distinction of benign from malignant tumors is crucial. In addition, the
increasing routine use of ultrasound (US) has substantially increased
the number of testicular incidentalomas requiring work-up and
treatment.
The few clinical features proposed as suggestive of LCTs include
gynecomastia and precocious puberty (Mameli et al., 2016; Santos-Silva
et al., 2014). To our knowledge, few studies describe the clinical char-
acteristics of LCTs, and they involved small series, different institutions,
and different protocols, and mainly dealt with the surgical manage-
ment of these tumors (Borghesi et al., 2015; Bozzini et al., 2013;
Bozzini et al., 2017; Carmignani et al., 2003; Djaladat, 2015; Giannarini
et al., 2008; Giannarini et al., 2007; Laclergerie et al., 2017; Leon-
hartsberger et al., 2014; Leonhartsberger et al., 2011; Loeser et al.,
2009; Maxwell et al., 2016; Nason et al., 2017; Nicolai et al., 2015;
Scandura et al., 2018). None reported clinical data from long-term
follow-up.
We therefore felt the need to analyze the clinical, biochemical,
and radiological features of all patients with LCTs referred to our
department over a 10-year period and describe the outcome of
the various treatment options. A distinctive feature of the present
analysis is that all patients were investigated prospectively on the
basis of an established protocol using novel diagnostic techniques
and were surgically treated and followed up in the same unit, thus
minimizing biases in data accrual, analytical methods, and therapeutic
outcome.
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Materials and Methods
Patients and protocol
The study was carried out from June 2009 to June 2018 at the
Sapienza University of Rome using the STARD (STAndards for the
Reporting of Diagnostic accuracy studies) checklist flow diagram. Of
the 9949 inpatients and outpatients referred for scrotal US, 282 were
diagnosed with at least one solid testicular lesion (inclusion crite-
rion). Of these, 95 had a palpable lesion and underwent surgical
exploration because of the high pre-test probability of malignancy
(exclusion criterion); the nodule was malignant in 92 patients (96%;
the remaining three patients had non-neoplastic lesions). The remaining
187menwith incidental, nonpalpable testicular lesions were included in
the study.
The study design is shown in Fig. 1. The local review board approved
the protocol, which was conducted in accordance with the Declaration
of Helsinki, and all patients provided written informed consent. We
included all the patients screened for the ALCeP trial (ClinicalTrials.
gov Identifier: NCT01206270).
The enrolled subjects underwent medical history and clinical
examination and were asked to undergo routine blood tests,
hormone investigations [FSH, LH, total testosterone, estradiol,
inhibin B, sex hormone-binding globulin (SHBG), prolactin (PRL)],
and semen analysis. Serum FSH, LH, and PRL were measured in
duplicate with the chemiluminescent microparticle immunoassay
(CMIA, Architect System) (Abbott Laboratories, IL, USA), with
limits of detection (LOD) of 0.05 U/l, 0.07 U/l, and 0.6 ng/ml,
respectively; the intra- and inter-assay coefficients of variation for
our laboratory were 2.9% and 3.7% at 4.1 U/l (FSH); 3.2% and
4.6% at 3.7 U/l (LH); and 3.5% and 4.2% at 5.8 ng/ml (PRL). The
normal reference ranges were 1.38–9.58 mIU/ml for FSH, 1.8–
8.16 mIU/ml for LH, and 2.6–13.13 nh/ml for PRL. SHBG was
analysed by CMIA (Abbott Laboratories, IL, USA); the LOD was
≤0.1 nmol/l, the intra-assay and inter-assay coefficients of variation
for our laboratory were 5.65% and 9.54% at 8.8 nmol/l, respectively,
and the normal reference range for adulthood was 11.2–78.1 nmol/l.
Serum inhibin B was measured using an enzymatically amplified two-
site, two-step sandwich immunoassay (ELISA) (Diagnostic Systems
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Figure 1 Flow diagram for study of patients with lesions of the testis.US: ultrasound; CEUS: contrast enhanced ultrasonography; MRI:
magnetic resonance imaging; LCTs: Leydig cell tumors.
Laboratories, Inc. Webster, TX, USA). The LOD was 7.0 pg/ml, the
intra and interassay coefficients of variation were 3.3% and 7.2%,
respectively, at 122 pg/ml, and the normal post-pubertal range
was 80–380 pg/ml. Steroid hormones were evaluated by liquid
chromatography–mass spectrometry (triple-quadrupole AGILENT
series 1290 INFINITY II/6495MSD at BioL&endo LAB Sapienza,
University of Rome). Themethod’s precision for pools at low, medium,
and high concentrations was 2.7–2.9% for testosterone and 3.3–5.3%
for estradiol.
Semen samples were collected by masturbation directly into a sterile
plastic container after 2–7 days of sexual abstinence. They were
examined by light microscope and were then assessed according to
World Health Organization guidelines (World Health Organization,
1999;World Health Organization, 2010). The following variables were
taken into consideration: volume (ml), sperm concentration (n/ml),
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total sperm number (n × 106/ejaculate), progressive motility (%), and
morphology (% abnormal forms).
Patients who consented also underwent contrast-enhanced ultra-
sound (CEUS), elastography, gadolinium-enhanced scrotal magnetic
resonance imaging (MRI), and hCG stimulation test (5000 IU i.m., IBSA
Pharmaceuticals, Italy) with serum total testosterone and estradiol
measured at 0, 24, 48, and 72 hours. The comparison cohorts consisted
of the 90 patients diagnosed with seminoma (from the 187 with
nonpalpable lesions, Fig. 1) and patients without testicular nodules
(NoL group) matched for age and body mass index (BMI), selected
from patients screened for infertility using a similar protocol. The
seminoma cohort was chosen because this is the most common ‘pure’
histotype (Albers et al., 2015) and has US features closest to those
of LCTs, as previously shown (Isidori et al., 2014; Manganaro et al.,
2018; Manganaro et al., 2015; Pozza et al., 2016). Data on some of the
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included patients have been presented in part in previous publications
(Isidori et al., 2014; Manganaro et al., 2018; Manganaro et al., 2015;
Pozza et al., 2016).
Diagnosis of LCTs, reference standard, and
follow-up
After US diagnosis of a testicular lesion, tumor markers (β-HCG,
placental alkaline phosphatase, alpha-fetoprotein, carcinoembryonic
antigen, ferritin, and lactate dehydrogenase) were investigated in all
patients and the following additional tests were offered to attempt pre-
operatively to distinguish LCTs from malignant neoplasms: CEUS, tes-
ticular elastography, and scrotal MRI with gadolinium contrast enhance-
ment. All patients with solid lesions were sent for tissue sparing surgery
(TSS) with the awareness that some lesions might turn out to be
benign, as current guidelines do not address the management of solid,
potentially neoplastic lesions. On histology, signs of malignancy in
LCTs were reported according to Kim’s criteria (tumor size, necrosis,
presence of nuclear atypia, angiolymphatic invasion, infiltratingmargins,
and number of mitotic features) (Kim et al., 1985). On immunochem-
istry, inhibin and calretinin were used as confirmatory markers for the
diagnosis of LCTs.
If the lesion was malignant on frozen section, the procedure was
converted to a radical orchiectomy (RO). When patients declined
surgery and the clinical and US findings allowed a ‘watchful-waiting’
approach, they were followed up with serial US every 3 months for
a minimum of 12 months, provided they had had a previous negative
abdominal computed tomography (CT) scan or MRI and a negative
chest X-ray or CT scan, thus excluding distant metastasis.
For diagnosis, we considered LCT as any histologically confirmed
lesion or any single, hypoechoic, vascularized solid lesion showing res-
olution, no growth, no elevated tumor markers, and no other relevant
clinical events (gynecomastia, flushes, sweating, polycythemia, etc.)
at repeated follow-up, according to a previously validated protocol
(Isidori et al., 2014; Manganaro et al., 2015).
Statistical analysis
Groups were compared using the Mann–Whitney test for continuous
variables or odds ratio with 95% confidence intervals (CIs) for categori-
cal variables. Relationships between the qualitative data were examined
by chi-square test or Fisher’s exact tests.
Statistical analyses were performed with SPSS 17.0 [SPSS, Chicago,
IL, USA] and SygmaPlot 12.0 [Systat Software Inc., CA, USA] by using
two-tailed significance tests, with P < 0.05 considered indicative of
statistical significance.
Results
Nonpalpable testicular tumors were found in 2.72% of the nearly
10 000 consecutive unselected patients referred to the Testis Unit over
a 10-year period. Of these, 1.89% had a malignant, and 0.84% a benign,
testicular lesion. Eighty-three patients were diagnosed with LCTs and
194 with malignant testicular lesions demonstrating a high prevalence
of LCTs among nonpalpable masses in our cohort (30%, Table I). The
reasons for referral for the entire set of patients diagnosed with a
tumor are reported in Table II. The majority of patients with LCT was
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referred for infertility (48.2%), general andrological screening (10.8%),
or varicocele (9.6%).
The comparison cohort consisted of an age- and BMI-matched group
(n =2683) selected from the 9678 subjects without solid testicular
lesions, who had a normal karyotype and underwent semen and
hormone evaluation. The clinical features of all subjects are shown in
Table III, while baseline hormone and semen parameters are shown in
Table IV. Patients with Klinefelter syndrome are presented separately
in Table III.
Clinical characteristics
Age at referral was similar for both patient groups (P =0.183), as
were height, weight, BMI, and mother’s age at delivery. The semi-
nomas were larger than the LCTs (P =0.049). Global testicular vol-
ume (GTV= right+ left volume) was similar in both patient groups
(P =0.081), with a trend toward smaller testes in the LCT group [23.1
(18.2–29.7) versus 26.0 (21.4–33.4)]. Compared to the NoL group,
patients with LCTs had significantly smaller GTV (P =0.017).
In the seminoma group, 11 patients (12.2%) had a previous contralat-
eral malignant tumor compared to none in the LCT group (P =0.001).
Conversely, five of the patients with LCT (6%) had a previous con-
tralateral LCT, compared to none in the seminoma group (P =0.024).
The groups had a similar history of undescended testis (P =0.680) and
gynecomastia (P=0.196). Both cryptorchidism and gynecomastia were
more common in LCT patients than in the NoL group (P < 0.001).
Laboratory data
Patients with LCTs showed lower sperm concentration (P =0.029)
and lower total sperm number (P =0.011) than the seminoma and
NoL groups (Table IV). Total sperm motility in the LCT group was
lower than in the seminoma group (P =0.049) and normal morphology
was lower than in the NoL group (P < 0.001) (Table IV). SHBG was
higher in the LCT group than in the seminoma group (P =0.018) or
NoL group (P < 0.001). There was no statistically significant difference
in gonadotrophins, total testosterone, or inhibin B between the two
tumor groups. Compared to the NoL group, patients with LCTs
showed higher levels of FSH (P < 0.001) and LH (P < 0.001) and a
lower testosterone/LH ratio (P < 0.001).
Diagnostic features of LCTs
Themajority of LCTs (68, 81.9%) appeared hypoechoic, while 13 were
weakly hypoechoic (14.5%) and two inhomogeneous (3.6%). Internal
vascularization was seen in 54 LCTs (65.1%). The margins were well-
defined in 59 cases (71.1%), ill-defined in 17 (20.5%), and irregular in
7 (8.4%). None of the lesions presented intralesional calcifications;
parenchymal microlithiasis was present in 14 cases (16.8%) (Fig. 2).
Of the 59 patients who underwent CEUS, 50 showed features
suggestive of LCTs according to the published criteria (Isidori et al.,
2014), characterized by a rapid enhancement of the lesion (wash-
in) and a delayed wash-out compared with that of the surrounding
parenchyma. Five cases showed synchronous wash-in and wash-out
and the remaining four lesions showed a rapid wash-in and wash-
out pattern. Elastography was performed in 54 patients. Nine lesions
(10.8%) were soft (ES1), 24 (28.9%) had a medium elasticity (ES2), and
the remaining 21 (25.3%) were hard (ES3). Scrotal MRI data were avail-
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Table II Reasons for referral in patients with LCTs and seminoma.
Reason for referral
.....................................................................................................................................................
LCTs Seminomas P∗
......................................................................................................................................................
Infertility 40/83 (48.2) 23/90 (25.6) 0.002
General andrological screening 9/83 (10.8) 19/90 (21.1) 0.110
Varicocele 8/83 (9.6) 7/90 (7.8) 0.663
Klinefelter’s syndrome 6/83 (7.2) 0/90 (0) 0.001
Testicular pain 6/83 (7.2) 6/90 (6.7) 1.000
Gynecomastia 2/83 (2.4) 0/90 (0) 0.228
Not known 2/83 (2.4) 18/90 (20.0) /
Hypogonadism 2/83 (2.4) 0/90 (0) 0.228
Inguinal lymphadenopathy 0/83 (0) 1/90 (1.1) 1.000
Microlithiasis 0/83 (0) 1/90 (1.1) 1.000
Hydrocele 1/83 (1.2) 0/90 (0) 0.479
Previous cryptorchidism 1/83 (1.2) 0/90 (0) 0.479
Erectile dysfunction 1/83 (1.2) 2/90 (2.2) 1.000
Follow-up of a previous contralateral
malignant tumor
0/83 (0) 11/90 (12.2) 0.001
Follow-up of a previous LCT 5/83 (6.0) 0/90 (0) 0.041
∗LCTs versus seminomas. Relations between the qualitative data were examined by chi-square test or Fisher’s exact tests.
able for 37 patients: 25 lesions (67.6%) showed amarkedly hypointense
signal on T2-WI and a rapid and marked wash-in followed by a
prolonged washout, all features suggestive of LCT (Manganaro et al.,
2015). Five (13.5%) showed an uncertain response and the remaining
seven lesions (18.9%) showed a weak and progressive wash-in.
Some studies (Bandak et al., 2017; Zarrilli et al., 2000) suggest that
response to hCG may be helpful in the diagnosis of LCT. In our
cohorts, hCG data were available for 10 patients with LCTs and 14
patients without testicular lesions. After hCG injection, serum total
testosterone and estradiol increased significantly against baseline in
both groups. Peak testosterone (48 h) and estradiol (24 h) levels were
slightly higher in the LCT group than in the control group (respec-
tively P =0.001 and P =0.021, Fig. 3). Consistent with the increased
steroidogenic production in LCT, the AUC values were higher in LCT
patients than in the NoL group for testosterone (P =0.003), but not
estradiol (P =0.070).
Management and follow-up
Histological confirmation was proposed to all patients with a testicular
solid lesion. TSS or RO was recommended according to the patient’s
history, size of the lesion, and specific individual needs. Intrasurgical
US was used to locate nonpalpable tumors during surgery. LCTs
were diagnosed surgically in 51 cases (40 by TSS and 11 by RO)
and, in the 32 patients (38.5%) who declined surgery, by the lack
of change in symptoms during surveillance. The lesion affected the
right testis in 46 cases and the left in 37. No operated LCTs showed
histological signs of malignancy (Kim et al., 1985), except for two
cases that showed a higher mitotic index and higher MIB-1 activity (a
proliferation marker) and for this reason were considered ‘high-grade’
LCTs.
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The median duration of follow-up was 66 months, ranging from 12
to 144 months for the whole cohort, 6 to 120 months (median, 60)
for those treated with TSS, 24 to 144 months (median, 96) for those
treated with orchiectomy, and 22 to 144 months (median, 60) for the
surveillance group. During the prospective observational period, no
patient had a distant metastasis and all patients were alive without
evidence of disease at last data cut-off. Two patients were found to
have high-grade LCTs on histology (mitotic index, >10); they were
both treated with TSS (tumor size, 0.5 cm and 0.6 cm, respectively)
and were disease-free at their last follow-up visit (60 and 84 months).
Five patients had a previous history of LCTs (recurrence rate 6.0%);
two of these had undergone orchiectomy 21 and 7 years, respectively,
before study entry, and three had undergone TSS 6, 6m and 4 years,
respectively, before study entry. Four of these recurrences were
contralateral and one was ipsilateral. The recurrence rate for malignant
tumors was 12.2% (11/90 patients).
The changes in hormone and semen parameters in relation to
treatment strategy are reported in Table V. No major differences were
found in response to treatment comparing the baseline with follow-up
at 6 or 12 months, suggesting that enucleation was not superior to
active surveillance in improving biochemical and semen parameters.
However, of the four patients with gynecomastia, two reported an
improvement after enucleation of the lesion. One of the remaining two
patients underwent surgical correction.
Follow-up reproductive data was available for 28 of the 40 LCT
patients initially referred for infertility. Four patients reported fathering
a natural pregnancy (one patient in the surveillance group and three in
the TSS group) and four reported successful ART (one RO, two TSS,
one in the surveillance group). Of the remaining patients, four failed
ICSI (one RO, two TSS, one surveillance), and 16 were not seeking
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Figure 2 Examples of the appearance of LCTs. B-mode images are shown on the left side of each panel and correspondent color Doppler
appearance is shown on the right. Panel A shows a 0.5 cm hyperechoic lesion; panel B shows an inhomogeneous lesion of 1.1 cm; panels C,D, and E
show three hypoechoic LCTs, respectively, 0.4 cm, 0.5 cm, and 0.8 cm; all the lesions show internal vascularization (see right side), identified as LCTs at
histology.
children. Twenty-two patients (26.5%) started testosterone therapy
following the development of symptomatic subclinical hypogonadism
(6 patients) or manifest hypogonadism (16 patients).
Discussion
The present study reports the clinical, hormonal, seminal, and radio-
logical features and long-term follow-up data of the largest cohort of
patients with LCTs evaluated prospectively using a uniform protocol
from a single referral center.
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The main findings were as follows: LCTs are strongly associated
with male infertility, cryptorchidism, and gynecomastia, supporting
the hypothesis that testicular dysgenesis syndrome (TDS) plays
a role in the development of these tumors; the impairment in
the tubular and stromal compartment observed in the testes of
patients with LCTs seems independent of the tumor itself, as it
does not improve after surgery and appears worse than in the
seminoma group; no single test is 100% accurate in preoperatively
distinguishing LCTs from germ cell tumors, but the novel diagnostic
techniques CEUS and MRI proved reliable; management of patients
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Figure 3 Changes in patient serum hormone levels measured at 0, 24, 48, and 72 hours before and after hCG injection. hGC
(5000 IU) was administered i.m. Peak testosterone (48 h) and estradiol (24 h) levels were slightly higher in the LCT group than in the control group.
Consistent with the increased steroidogenic production in LCT, the AUC values were higher in LCT patients than in the NoL (patients without testicular
lesions) group for testosterone, but not estradiol. hCG test data were available for 10 patients with LCTs and 14 patients without testicular lesions.
Data are mean± SD.
with LCTs requires attention to preserving fertility, and TSS should
therefore replace RO; in compliant patients, active surveillance through
clinical and radiological follow-up is a safe alternative option for
small LCTs.
In the infertile population, testicular tumors have been reported
as 20-fold more frequent than in the general population, due to
screening and related disorders identified as risk factors (cryp-
torchidism, Klinefelter’s syndrome, or gonadal dysgenesis syndrome)
(Raman et al., 2005). The recent literature includes several series
of small incidental, asymptomatic, non-palpable testicular tumors
discovered due to the increase in referrals for scrotal US (Ates et al.,
2016; Bozzini et al., 2013; Carmignani et al., 2004; Colpi et al., 2005; De
Stefani et al., 2012; Djaladat, 2015; Drudi et al., 2016; Eifler et al., 2008;
Galosi et al., 2016; Gentile et al., 2013; Giannarini et al., 2007; Hopps
and Goldstein, 2002; Isidori et al., 2014; Lagabrielle et al., 2018; Leroy
et al., 2003; Ma et al., 2017; Mancini et al., 2007; Muller et al., 2006;
Paffenholz et al., 2018; Powell and Tarter, 2006; Raman et al., 2005;
Scandura et al., 2018; Sheynkin et al., 2004; Shilo et al., 2012a; Shilo
et al., 2012b). Most of these studies demonstrated a high prevalence
of LCTs among nonpalpable masses, with an overall mean prevalence
value of 26.6% [18.3–34.9 95% CI] (Table I), in contrast to large
palpable testisticular tumors, which are malignant in >90% of cases
(Bozzini et al., 2013, Elert et al., 2002; Giannarini et al., 2008; Sheynkin
et al., 2004). Paffenholz et al. (2018) reported the lowest prevalence
of LCTs (1.7%) in 9 of 522 patients operated on for testicular lesions.
However, only lesion volume (cm3) was reported and therefore it
is likely that the larger sizes inflated the number of malignancies. In
line with these reports, even using the most conservative approach—
i.e. considering only histologically confirmed lesions and excluding
all follow-up diagnoses—the prevalence of LCTs in our series was
26% (51 of all the 187 nonpalpable lesions detected in the entire
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
study period). These data make it imperative to study the origin,
related symptoms, and natural history of this ‘not-so-rare’ endocrine
tumor.
It is hypothesized that many cases of abnormal spermatogenesis,
cryptorchidism, penile malformations, and testicular cancer may have
a common etiology, such as an irreversible developmental disorder
originating in early fetal life and resulting in TDS (Joensen et al., 2008).
Leydig cell hyperplasia is a frequent finding in patients with impaired
spermatogenesis and other TDS-related disorders, often in the form
of large clusters called micronodules (Joensen et al., 2008; Soerensen
et al., 2016; Tarsitano et al., 2018). Leydig cell micronodules, defined
as more than 15 Leydig cells in a cross-section, have previously been
associated with a low testosterone/LH ratio, reflecting an endocrine
dysfunction (Joensen et al., 2008). Hormone impairment was observed
in our cohort in both LCT and seminoma groups when compared to
the NoL group. The reason for the growth of Leydig cell micronodules
in hypogonadal men is unknown, but it has been speculated that it
reflects primary Leydig cell failure as a result of TDS. This could in
turn raise LH levels to compensate for impaired testosterone syn-
thesis, causing chronic Leydig cell compartment hyperstimulation, a
mechanism that was described by Christensen et al. as inducing Leydig
cell hyperplasia/adenoma in rats (Christensen and Peacock, 1980).
Although LH plays an important role in Leydig cell proliferation, the
maturation and proliferation of these cells is also affected by many
other paracrine and endocrine signals, including anti-Müllerian hor-
mone, inhibin, and other growth factors (Joensen et al., 2008). Samson
et al. (2004) found that endocrine gland-derived vascular endothelial
growth factor (EG-VEGF), a human angiogenic mitogen, is expressed
in the Leydig cells of human fetal testes from 14 weeks’ gestation, and
that EG-VEGF–mediated angiogenesis at this stage is induced by LH
and appears critical for normal testicular homeostasis. Furthermore,
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Table V Changes in hormone and semen measures after surgical enucleation or during active surveillance.
LCTs
.................................................................................................................
Enucleation Group Surveillance Group
..................................................... .....................................................
Baseline 6–12 months
follow-up
Baseline 6–12 months
follow-up
....................... ....................... ....................... .......................
n 40 40 32 32 n.r.
.....................................................................................................................................................................................
FSH (mIU/ml) 4.9 (2.4–32.1) 6.8 (5.3–24.22) 10.1 (6.6–29.6) 16.4 (6.0–25.3) 1.38–9.58
LH (mIU/ml) 5.8 (2.7–7.2) 5.5 (3.6–6.9) 4.9 (3.5–7.4) 6.4 (3.5–9.8) 1.8–8.16
Te (nmol/l) 20.5 (13.0–24.7) 18.7 (9.0–25.7) 19.0 (14.4–20.1) 17.7 (13.0–25.8) 10.4–38.2
SHBG (nmol/l) 32.8 (26.4–40.0) 34.0 (25.4–34.0) 46.2 (39.6–55.7) 55.3 (36.3–67.7) 11.2–78.1
E 2 (pg/ml) 25.0 (12.5–25.0) 15.1 (9.2–46.7) 25.7 (19.8–37.5) 25.0 (16.0–25.0) 25–107
InhB (pg/ml) / / 80.6 (47.0–117.5) 85 (52.0–102.0) 80–380
Prolactin (ng/ml) 21.1 (8.4–35.1) 17.0 (8.5–48.5) 10.9 (5.1–16.5) 18.4 (9.0–18.4) 2.6–13.13
Te/LH ratio 4.1 (2.0–6.3) 2.7 (1.3–5.2) 3.2 (2.0–7.0) 1.4 (1.2–1.6) /
Te/E 2 ratio 0.6 (0.4–0.8) 1.0 (0.4–2.0) 0.7 (0.5–0.9) 0.5 (0.5–0.7) /
Volume (ml) 2.3 (1.6–3.4) 2.5 (1.3–3.8) 2.2 (1.2–2.7) 2.0 (1.6–2.3) 3.7 (1.5–6.8)
pH 7.5 (7.4–7.6) 7.5 (7.4–7.6) 7.4 (7.2–7.6) 7.5 (7.5–7.6) >7.2
Sperm concentration
(106/ml)
4.5 (0.1–31.5) 3.0 (0.3–33.0) 12.0 (0.1–70.0) 8.0 (3.0–57.0) 73 (15–213)
Total sperm number
(106/ejaculate)
15.7 (0.4–57) 9.3 (1.2–58.5) 30.0 (0.4–57) 12.0 (6.0–136.0) 255 (39–802)
Total motility (%) 15.0 (0–40.2) 15.5 (0–28.7) 10.0 (0–50) 25.0 (7.5–42.5) 61 (40–78)
Normal morphology (%) 4.5 (0–22.5) 5.5 (0–17.7) 10.0 (0–22.0) 10.0 (4.0–18.5) 15 (4–44)
Leukocyte count (106/ml) 0.4 (0.2–0.6) 0.6 (0.2–1.0) 0.8 (0.3–1.0) 0.6 (0.3–0.8) <1.0
Values are expressed as median and interquartile ranges. Groups were compared using the Mann–Whitney test for paired data.
they found that EG-VEGF secretion can promote the growth of LCTs,
suggesting a role for the LH signaling pathway in tumor progression.
Whether or not LCTs derive from degenerated islets of Leydig
cell hyperplasia remains unknown, and the molecular steps leading
to tumor transformation merit further study. Hormone evaluation in
our cohort showed that patients with LCT had significantly higher
gonadotrophin and lower testosterone levels than the controls, even
if they were still within the ‘normal’ range. We also found higher levels
of SHBG in the LCT group than in either the seminoma or NoL group.
The latter finding may reflect abnormal estrogen secretion from LCTs,
but could alsomitigate some of the clinical symptoms of steroid excess,
given that SHBG lowers levels of bioavailable androgens. Patients with
LCTs had a lower sperm concentration, lower total sperm number,
and reduced sperm motility and morphology compared to subjects
without testicular lesions. Our findings point toward an impairment
in the tubular and stromal compartments of the affected testes that
persists even after removal of the tumor.
Testicular volume was reduced in 40% of patients with LCTs, con-
firming that these tumors tend to occur in morphologically and func-
tionally compromised testes. The higher prevalence of cryptorchidism
(15.6%) suggests that this risk factor, traditionally linked only to germ
cell tumors, should also be considered in relation to LCTs, as hypoth-
esized in the TDS model (Soerensen et al., 2016).
Most patients with LCTs were asymptomatic and the mass was
discovered incidentally. The typical symptoms and signs associated with
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LCTs, including gynecomastia, were less frequent in our series (4.8%)
compared to literature reports (Narula and Carlson, 2014). In contrast
with baseline values, hCG testing revealed a slightly higher stimulated
testosterone and estradiol output in LCTs than in the NoL group.
The use of second-level investigations (namely CEUS and MRI)
allowed us to correctly identify the majority of cases prior to surgery.
Active surveillance is feasible only when both tests are consistent with
a diagnosis of LCT and, conversely, RO should be considered when
both are suggestive of seminoma. The rationale for an active surveil-
lance strategy is reinforced by the fact that surgical resection—albeit
associated with excellent results and very few side effects—did not sig-
nificantly improve the biochemical and seminal output. A conservative
approach is particularly important in infertile or monorchid patients.
The long follow-up period of up to 144 months (median 66 months)
is a unique feature of the present study. All patients were disease-free
at last visit regardless of the adopted therapeutic choice, reinforcing the
fact that the conservative approach appears safe in LCTs. Interestingly,
a significant proportion of LCTs were recurrent or bilateral tumors,
adding weight to the concept of ‘organ-disease’. The seminoma
recurrence rate was also higher than previous literature reports
(Alber et al., 2015), but was in line with the current epidemiological
forecast, which predicts an increase in testicular tumors in southern
European countries (Park et al., 2018). At the last follow-up visit,
we observed that patients referred for infertility did not improve
their fertility potential after tumor resection, and only 28% had
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fathered children (whether naturally or through ART), while 26.5%
of the entire cohort had started testosterone therapy due to the
development of symptomatic subclinical hypogonadism (6/22) or
manifest hypogonadism (16/22). This supports the TDS hypothesis
and the need for prevention strategies (Olesen et al., 2018). In this
respect, cryopreservation could be considered in these patients straight
after diagnosis, and they should be monitored for hypogonadism later
in life.
Limitations
This study has some limitations. First, hCG and second-line diagnostic
investigations were not available for all tumor patients. Second, ours
is a referral center for infertility, thus a selection bias may have altered
the baseline features of the LCT population. However, given that the
comparison cohorts were also from the same center and had been
managed with a similar protocol, we do not expect a significant effect.
In contrast, the study also has several advantages: it is the largest cohort
of LCTs prospectively observed for a long period, it reports full data
on seminal, hormonal, imaging, and surgical outcome, and it has two
comparison cohorts.
Conclusion
LCTs are the most common stromal tumor of the testis and account
for a significant proportion of incidentally found small testicular tumors.
They have an excellent oncological prognosis. Active surveillance
appears a safe option, once the diagnosis is ascertained using the latest
imaging approaches. However, patients with LCTs are at greater risk of
endocrine and spermatogenesis abnormalities even when the tumor is
resected, and thus require long-term follow-up and prompt efforts to
preserve fertility after diagnosis.
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